Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Solaredge Technologies Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Solaredge Technologies Inc trades at $32.08 (market cap $2.00B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 6.3× Solaredge Technologies Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Solaredge Technologies Inc for 34 Days on average.
| HALO | SEDG | |
|---|---|---|
Market Cap | $12.58B | $2.00B |
Volume | 2,179,278 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $115.22 | $78.51 |
52-Week Low | $61.63 | $28.47 |
Typical Hold Time | 1 Days | 34 Days |
Enterprise Value | $14.49B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SolarEdge Technologies (SEDG) trades at $32.21, down 2.86% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net loss of $405.45M in 2025, with negative profit margins, though revenue grew to $1.18B. Recent news highlights legal investigations and volatility driven by solar sector pressures and new AI data center initiatives announced in September 2026.
The outlook remains cautious due to persistent losses and high debt, but analyst consensus suggests moderate upside to a $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures, and reliance on solar market recovery. Investment appeal hinges on execution of growth targets and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
